Trans-Tissue, Sustained Release of Gemcitabine from Photocured Gelatin Gel Inhibits the Growth of Heterotopic Human Pancreatic Tumor in Nude Mice

Hidenobu Okino, Ryo Maeyama, Tatsuya Manabe, Takehisa Matsuda, Masao Tanaka

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: Although gemcitabine, a deoxycytidine analogue, recently demonstrated improvements in the response rate for pancreatic cancer, the median survival for patients is limited to 4-6 months. The purpose of the present study was to develop trans-tissue delivery of gemcitabine, which is based on photocured gelatin gel immobilized with gemcitabine, and to validate whether such a system inhibits the growth of the pancreatic tumor in vivo. Experimental Design: The in vitro release profile of gel-embedded gemcitabine from a gel was examined based on in vitro chemosensitivity of AsPC1 cell (human pancreatic cancer cell line) for gemcitabine. The permeation of gel-embedded rhodamine B (used as a model drug) into tissues and inhibitory effect of tumor growth of photocured gelatin gel immobilized with gemcitabine were examined using in vivo s.c. tumor model of athymic mice. Results: The release profile was characterized as an initial burst of release, followed by a gradual release, irrespective of gelatin concentration. Rhodamine B permeated into the tumor and retained for at least 10 days. Photocured gelatin gel immobilized with gemcitabine significantly reduced the tumor volume compared with gemcitabine injection. Therapeutic success was correlated with decreased cell proliferation and increased cell apoptosis in tumor cells, supported by proliferating cell nuclear antigen and terminal deoxynucleotidyltransferase-mediated nick end labeling staining. Blood analysis and body weight measurement showed that little side effect was observed in this therapy. Conclusions: In situ trans-tissue gemcitabine delivery on the tissue with possibly remnant cancer cells using the drug-releasing matrix developed here is expected to reduce the rate of local recurrence for patients with pancreatic cancer.

Original languageEnglish
Pages (from-to)5786-5793
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number15
Publication statusPublished - Nov 15 2003

Fingerprint

gemcitabine
Gelatin
Nude Mice
Gels
rhodamine B
Growth
Neoplasms
Pancreatic Neoplasms
Deoxycytidine
DNA Nucleotidylexotransferase
Proliferating Cell Nuclear Antigen
Tumor Burden
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Trans-Tissue, Sustained Release of Gemcitabine from Photocured Gelatin Gel Inhibits the Growth of Heterotopic Human Pancreatic Tumor in Nude Mice. / Okino, Hidenobu; Maeyama, Ryo; Manabe, Tatsuya; Matsuda, Takehisa; Tanaka, Masao.

In: Clinical Cancer Research, Vol. 9, No. 15, 15.11.2003, p. 5786-5793.

Research output: Contribution to journalArticle

Okino, Hidenobu ; Maeyama, Ryo ; Manabe, Tatsuya ; Matsuda, Takehisa ; Tanaka, Masao. / Trans-Tissue, Sustained Release of Gemcitabine from Photocured Gelatin Gel Inhibits the Growth of Heterotopic Human Pancreatic Tumor in Nude Mice. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 15. pp. 5786-5793.
@article{80901a80700a46c69310f0b48b6071f4,
title = "Trans-Tissue, Sustained Release of Gemcitabine from Photocured Gelatin Gel Inhibits the Growth of Heterotopic Human Pancreatic Tumor in Nude Mice",
abstract = "Purpose: Although gemcitabine, a deoxycytidine analogue, recently demonstrated improvements in the response rate for pancreatic cancer, the median survival for patients is limited to 4-6 months. The purpose of the present study was to develop trans-tissue delivery of gemcitabine, which is based on photocured gelatin gel immobilized with gemcitabine, and to validate whether such a system inhibits the growth of the pancreatic tumor in vivo. Experimental Design: The in vitro release profile of gel-embedded gemcitabine from a gel was examined based on in vitro chemosensitivity of AsPC1 cell (human pancreatic cancer cell line) for gemcitabine. The permeation of gel-embedded rhodamine B (used as a model drug) into tissues and inhibitory effect of tumor growth of photocured gelatin gel immobilized with gemcitabine were examined using in vivo s.c. tumor model of athymic mice. Results: The release profile was characterized as an initial burst of release, followed by a gradual release, irrespective of gelatin concentration. Rhodamine B permeated into the tumor and retained for at least 10 days. Photocured gelatin gel immobilized with gemcitabine significantly reduced the tumor volume compared with gemcitabine injection. Therapeutic success was correlated with decreased cell proliferation and increased cell apoptosis in tumor cells, supported by proliferating cell nuclear antigen and terminal deoxynucleotidyltransferase-mediated nick end labeling staining. Blood analysis and body weight measurement showed that little side effect was observed in this therapy. Conclusions: In situ trans-tissue gemcitabine delivery on the tissue with possibly remnant cancer cells using the drug-releasing matrix developed here is expected to reduce the rate of local recurrence for patients with pancreatic cancer.",
author = "Hidenobu Okino and Ryo Maeyama and Tatsuya Manabe and Takehisa Matsuda and Masao Tanaka",
year = "2003",
month = "11",
day = "15",
language = "English",
volume = "9",
pages = "5786--5793",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Trans-Tissue, Sustained Release of Gemcitabine from Photocured Gelatin Gel Inhibits the Growth of Heterotopic Human Pancreatic Tumor in Nude Mice

AU - Okino, Hidenobu

AU - Maeyama, Ryo

AU - Manabe, Tatsuya

AU - Matsuda, Takehisa

AU - Tanaka, Masao

PY - 2003/11/15

Y1 - 2003/11/15

N2 - Purpose: Although gemcitabine, a deoxycytidine analogue, recently demonstrated improvements in the response rate for pancreatic cancer, the median survival for patients is limited to 4-6 months. The purpose of the present study was to develop trans-tissue delivery of gemcitabine, which is based on photocured gelatin gel immobilized with gemcitabine, and to validate whether such a system inhibits the growth of the pancreatic tumor in vivo. Experimental Design: The in vitro release profile of gel-embedded gemcitabine from a gel was examined based on in vitro chemosensitivity of AsPC1 cell (human pancreatic cancer cell line) for gemcitabine. The permeation of gel-embedded rhodamine B (used as a model drug) into tissues and inhibitory effect of tumor growth of photocured gelatin gel immobilized with gemcitabine were examined using in vivo s.c. tumor model of athymic mice. Results: The release profile was characterized as an initial burst of release, followed by a gradual release, irrespective of gelatin concentration. Rhodamine B permeated into the tumor and retained for at least 10 days. Photocured gelatin gel immobilized with gemcitabine significantly reduced the tumor volume compared with gemcitabine injection. Therapeutic success was correlated with decreased cell proliferation and increased cell apoptosis in tumor cells, supported by proliferating cell nuclear antigen and terminal deoxynucleotidyltransferase-mediated nick end labeling staining. Blood analysis and body weight measurement showed that little side effect was observed in this therapy. Conclusions: In situ trans-tissue gemcitabine delivery on the tissue with possibly remnant cancer cells using the drug-releasing matrix developed here is expected to reduce the rate of local recurrence for patients with pancreatic cancer.

AB - Purpose: Although gemcitabine, a deoxycytidine analogue, recently demonstrated improvements in the response rate for pancreatic cancer, the median survival for patients is limited to 4-6 months. The purpose of the present study was to develop trans-tissue delivery of gemcitabine, which is based on photocured gelatin gel immobilized with gemcitabine, and to validate whether such a system inhibits the growth of the pancreatic tumor in vivo. Experimental Design: The in vitro release profile of gel-embedded gemcitabine from a gel was examined based on in vitro chemosensitivity of AsPC1 cell (human pancreatic cancer cell line) for gemcitabine. The permeation of gel-embedded rhodamine B (used as a model drug) into tissues and inhibitory effect of tumor growth of photocured gelatin gel immobilized with gemcitabine were examined using in vivo s.c. tumor model of athymic mice. Results: The release profile was characterized as an initial burst of release, followed by a gradual release, irrespective of gelatin concentration. Rhodamine B permeated into the tumor and retained for at least 10 days. Photocured gelatin gel immobilized with gemcitabine significantly reduced the tumor volume compared with gemcitabine injection. Therapeutic success was correlated with decreased cell proliferation and increased cell apoptosis in tumor cells, supported by proliferating cell nuclear antigen and terminal deoxynucleotidyltransferase-mediated nick end labeling staining. Blood analysis and body weight measurement showed that little side effect was observed in this therapy. Conclusions: In situ trans-tissue gemcitabine delivery on the tissue with possibly remnant cancer cells using the drug-releasing matrix developed here is expected to reduce the rate of local recurrence for patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0345491963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345491963&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 5786

EP - 5793

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -